By: IPP Bureau
Last updated : December 02, 2025 9:44 am
Patients can now get the starting 2.5 mg dose for $299 per month
US pharma powerhouse Eli Lilly is cutting prices on its Zepbound (tirzepatide) single-dose vials, a move the drugmaker says will make the blockbuster obesity treatment more affordable for patients.
The lower-priced vials are now available through LillyDirect, the company’s digital health platform, marking the latest step in Lilly’s push to reduce out-of-pocket costs for people living with obesity.
The announcement follows last month’s pledge to cut prices on Zepbound multi-dose pens, pending FDA approval. By lowering vial prices as well, the company is broadening access across delivery formats.
With a valid prescription, patients can now get the starting 2.5 mg dose for $299 per month, the 5 mg dose for $399, and all other approved doses for $449 through the Zepbound Self Pay Journey Program.
"Far too many people who need obesity treatments still face cost and coverage barriers,” said Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities. “Today’s action underscores Lilly’s commitment to improving access across the obesity care landscape. We will keep working to provide more options – expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need.”
Zepbound is an injectable prescription medication designed to help adults with obesity—or adults who are overweight with weight-related medical problems—lose and maintain weight loss. It may also improve moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The drug contains tirzepatide and should not be used alongside any other tirzepatide-containing medicines or GLP-1 receptor agonists. It is not approved for children.
The treatment is available in a range of single-dose pen strengths—2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The 2.5 mg option is a starting dose only. Recommended weekly maintenance doses are 5 mg, 10 mg, or 15 mg for weight management, and 10 mg or 15 mg for OSA.